<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:hpo ids='HP_0005550'>Chronic lymphocytic leukemia</z:hpo> (CLL) is associated with an increased risk of developing <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, it is unknown whether CLL alters the disease course of these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> once they occur </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: <z:hpo ids='HP_0000001'>All</z:hpo> patients with <z:e sem="disease" ids="C0006142,C0678222" disease_type="Neoplastic Process" abbrv="">cancers of the breast</z:e> (n = 579,164), colorectum (n = 412,366), prostate (n = 631,616), lung (n = 489,053), kidney (n = 95,795), pancreas (n = 82,116), and ovary (n = 61,937) reported to the SEER program from 1990 to 2007 were identified </plain></SENT>
<SENT sid="3" pm="."><plain>Overall survival (OS; <z:hpo ids='HP_0011420'>death</z:hpo> resulting from any cause) and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival were examined, comparing patients with and without pre-existing CLL </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>-specific survival was evaluated for each <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> type in a site-specific manner (eg, <z:hpo ids='HP_0011420'>death</z:hpo> resulting from <z:hpo ids='HP_0003002'>breast cancer</z:hpo> in a patient with <z:hpo ids='HP_0003002'>breast cancer</z:hpo>) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Patients with <z:e sem="disease" ids="C0006142,C0678222" disease_type="Neoplastic Process" abbrv="">cancers of the breast</z:e> (hazard ratio [HR], 1.70; P &lt; .001), colorectum (HR, 1.65; P &lt; .001), kidney (HR, 1.54; P &lt; .001), prostate (HR, 1.92; P &lt; .001), or lung (HR, 1.19; P &lt; .001) had inferior OS if they had a pre-existing diagnosis of CLL after adjusting for age, sex, race, and disease stage </plain></SENT>
<SENT sid="6" pm="."><plain>These results for OS remained significant for patients with <z:e sem="disease" ids="C0006142,C0678222" disease_type="Neoplastic Process" abbrv="">cancers of the breast</z:e>, colorectum, and prostate after excluding or censoring CLL-related <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>-specific survival was also inferior for patients with <z:e sem="disease" ids="C0006142,C0678222" disease_type="Neoplastic Process" abbrv="">cancers of the breast</z:e> (HR, 1.41; P = .005) and colorectum (HR, 1.46; P &lt; .001) who had pre-existing CLL after adjusting for age, sex, race, and disease stage </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Inferior OS and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival was observed for several common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in patients with pre-existing CLL </plain></SENT>
<SENT sid="9" pm="."><plain>Additional studies are needed to determine the optimal management of these <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in patients with CLL and whether more aggressive screening or alternative approaches to adjuvant therapy are needed </plain></SENT>
</text></document>